期刊文献+

三阴性乳腺癌的临床病理特点与预后因素分析 被引量:3

The Clinical Pathologic Characteristics and Prognosis-relevant Subgroups of Triple-negative Breast Cancer
下载PDF
导出
摘要 三阴性乳腺癌的定义为雌激素受体、孕激素受体和人表皮生长因子受体2均为阴性表达的一类乳腺癌,约占所有乳腺癌的15%~20%,具有独特的生物学特征和临床病理特点。通常发生于绝经前的女性,发病年龄低,组织病理分级高,多为浸润性导管癌,淋巴结转移阳性率高,易发生复发及远处转移,因缺少有效的治疗手段,其预后较差。因此,研究其预后因素对指导三阴性乳腺癌的治疗有重要的意义。本文意在阐述三阴性乳腺癌的临床病理特点和影响其预后的因素。 Triple-negative breast cancer (TNBC) is clinically defined by the lack of expression of estrogen receptor, progesterone receptor, and the absence of amplification or overexpression of HER-2. TNBC, 15%-20% of all breast cancers,is characterized by distinct biological and clinical pathological features. It is more in premenopausal women and has the characters of young onset age, high histopathologic grade, more in infiltrating ductal carcinoma, high positive rate of lymph node metastasis and also a high incidence of local recurrence and distant metastasis. TNBC has a worse prognosis because of bad biology behaving and the lake of effective therapeutic targets. So, studying prognostic factors of which is significant to direct the cure. The aim of this study is to clarify the clinical pathologic characteristics and prognosis-relevant subgroups of TNBC.
出处 《医学与哲学(B)》 2015年第12期50-53,共4页 Medicine & Philosophy(B)
基金 辽宁省科技厅项目 项目编号:2009225009-5
关键词 三阴性乳腺癌 临床病理特点 预后相关因素 分子标志物 triple-negative breast cancer, clinical pathologic characteristics, prognosis-relevant subgroups, biological marker
  • 相关文献

参考文献24

  • 1赵夷,胡婷嫣,于辉,李锦成.三阴性乳腺癌两个新辅助化疗疗效比较[J].医学与哲学(B),2014,35(8):27-28. 被引量:7
  • 2Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gcne expression data sets[J]. Proc Natl Acad Sci U S A,2003,100(14):8418-8423.
  • 3Brenton J D,Carey I. A,Ahmed A A,et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical appli- cation?[J]. J Clin 0ncol,2005,23(29) :7350-7360.
  • 4Lin N U, Vanderplas A, Hughes M E, et al. Clinicopathologic lea tures, patterns of recurrence, and survival among women with tri pie negative breast cancer in the National Comprehensive Cancer Network[J].Cancer,2012,118(22):5463- 5472.
  • 5Rauh C, Gass P, Heusinger K, et al. Association of molecular sub- types with breast cancer risk factors:a case only analysis[J]. Eur J Cancer Prev,2015,24(6) :484-490.
  • 6Steward L,Conant 1.,Gao F,et al. Predictive factors and patterns of recurrence in patients with triple negative breast caneer[J]. Ann Surg Oncol,2014,21(7):2165-2171.
  • 7Rouzier R,Perou C M,Symmans W F,et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res,2005,11(16):5678-5685.
  • 8Carey I. A,Dees E C,Sawyer I.,et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesEJ2. Clin Cancer Res,2007,13(8) :2329-2334.
  • 9Ghosn M, Hajj C, Kattan J, et al. Triple-negative breast cancer in Lebanon:a case series[J]. Oncologist,2011,16(11):1552 -1556.
  • 10Limbada R,Slater A,Jain A. PB. 53 :are ethnic minorities more like ly to develop triple-negative breast cancer? A systematic review [J]. Breast Cancer Res, 2013,15 (Suppl 1 ) : 53.

二级参考文献12

  • 1Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior breast cancersubtypes[J].JClinOncol,2010,28(20):3271- 3277.
  • 2Amos K D.Adamo Bv Anders C Kv et a1. Triple-negative breast cancer: an update on neoadjuvant clinical trials[J]. Int J Breast Cancer, 2012. 2012: 385978.
  • 3Tischkowitz M.Brunet J Sv Begin L R.et a1. Use of immunohistochemical markers can refine prognosis in triple negative breast caneere]]. BMC Cancer,2007. 7: 134.
  • 4Rastogi P. Anderson S J. Bear H D. et a!. Preoperative chemotherap updates of national surgical adjuvant breast and bowel projeprotocols B-18 and B-27[J]. J Clin Onco1.2008.26(S) :778-785.
  • 5Berry D A, Cirrineione C, Henderson I C. et a1. Estrogen-receptor status and outcomes of modem chemotherapy for patients with node-positive breast cancer[J]. AMA.2007 .29S(20) :1658-1667.
  • 6Byrski T. Gronwald J. Huzarski T. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy [J]. J Clin Onco1.2010.28(3) :375-379.
  • 7Sliver D P. Richardson A L, Eklund A C. et al. Efficacy of neodjuvant Cisplatin in triple-negtive breast cancer[J]. J Clin Oncol , 2010. 28(7): 1145-11S3.
  • 8Cortazar P.Zhang L. Untch M,?: a!. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) [J]. Cancer Res, 2012. 72( 24 Suppl) : Abstract Sl - S11.
  • 9谢轶群,裔海鹰,包家林,吴莹.乳腺癌预后多因素研究的系统观[J].医学与哲学(B),2009,30(4):70-71. 被引量:3
  • 10肖宇,李惠平,雷玉涛,赵红梅,修典荣,王晶,王墨培,张淑兰,张照辉.乳腺癌新辅助化疗疗效及ER/PR,HER2,Ki67,CyclinA2的化疗预测作用[J].中国微创外科杂志,2011,11(2):163-167. 被引量:16

共引文献6

同被引文献34

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部